E-LIB Suche - Ergebnisse für: Perez-Fidalgo, J.A.

1

Lenvatinib plus pembrolizumab a new effective combination o..:

Perez-Fidalgo, J.A. ; Martinelli, E.
ESMO Open. 8 (2023) 2 - p. 101157 , 2023

Link: https://doi.org/10.1016/..

2

SEOM clinical guideline in ovarian cancer (2020):

Redondo, A. ; Guerra, E. ; Manso, L....
Clinical and Translational Oncology. 23 (2021) 5 - p. 961-968 , 2021

Link: https://doi.org/10.1007/..

3

Safety of assisted reproductive techniques in young women h..:

Condorelli, M. ; Bruzzone, M. ; Ceppi, M....
ESMO Open. 6 (2021) 6 - p. 100300 , 2021

Link: https://doi.org/10.1016/..

4

Olaparib in combination with pegylated liposomal doxorubici..:

Perez-Fidalgo, J.A. ; Cortés, A. ; Guerra, E....
ESMO Open. 6 (2021) 4 - p. 100212 , 2021

Link: https://doi.org/10.1016/..

5

BEECH: a dose-finding run-in followed by a randomised phase..:

Turner, N.C. ; Alarcón, E. ; Armstrong, A.C....
Annals of Oncology. 30 (2019) 5 - p. 774-780 , 2019

Link: https://doi.org/10.1093/..

6

Balixafortide (a CXCR4 antagonist) plus eribulin in HER2-ne..:

Kaufman, P.A. ; Pernas, S. ; Martin, M....
European Journal of Cancer. 92 (2018) - p. S117-S118 , 2018

Link: https://doi.org/10.1016/..

7

Erratum to: Recommendations for biomarker testing in epithe..:

Oaknin, A. ; Guarch, R. ; Barretina, P....
Clinical and Translational Oncology. 20 (2017) 3 - p. 424-424 , 2017

Link: https://doi.org/10.1007/..

8

Recommendations for biomarker testing in epithelial ovarian..:

Oaknin, A. ; Guarch, R. ; Barretina, P....
Clinical and Translational Oncology. 20 (2017) 3 - p. 274-285 , 2017

Link: https://doi.org/10.1007/..

9

160 AKT and/or mTOR inhibition as a potential target in tra..:

Perez-Fidalgo, J.A. ; Espin, E. ; Tormo, E....
European Journal of Cancer. 51 (2015) - p. S17 , 2015

Link: https://doi.org/10.1016/..

10

138 Deregulation of ARID1A, CDH1, cMET and PIK3CA and targe..:

Ibarrola-Villava, M. ; Llorca-Cardeñosa, M.J. ; Tarazona, N....
European Journal of Cancer. 51 (2015) - p. S11 , 2015

Link: https://doi.org/10.1016/..

11

Retrospective analysis of the use of G-CSF and its impact o..:

Pérez-Fidalgo, J. A. ; Bermejo, B. ; Chirivella, I....
Clinical and Translational Oncology. 16 (2014) 9 - p. 814-822 , 2014

Link: https://doi.org/10.1007/..

12

Subcutaneous trastuzumab: drug development and current posi..:

Martín Martorell, P. ; Bermejo de las Heras, B. ; Pérez-Fidalgo, J. A....
Clinical and Translational Oncology. 16 (2014) 10 - p. 859-864 , 2014

Link: https://doi.org/10.1007/..

13

Current questions for the treatment of advanced gastric can..:

Cervantes, A. ; Roda, D. ; Tarazona, N...
Cancer Treatment Reviews. 39 (2013) 1 - p. 60-67 , 2013

Link: https://doi.org/10.1016/..

14

Integrating radical local treatment of the primary in the m..:

Perez-Fidalgo, J.A. ; Caballero, A. ; Lluch, A.
European Journal of Surgical Oncology (EJSO). 38 (2012) 8 - p. 643-644 , 2012

Link: https://doi.org/10.1016/..

15

5040 Excision of primary tumour improves survival in metast..:

Pimentel, P. ; Pérez-Fidalgo, J. ; Caballero, A....
European Journal of Cancer Supplements. 7 (2009) 2 - p. 273 , 2009

Link: https://doi.org/10.1016/..